Issue 22
Time To Simplify ADR Calculation for Colonoscopy Quality Reporting
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jeffrey Lee, MD, MPH discuss “Evaluating Different Approaches for Calculating Adenoma Detection Rate: Is Screening Colonoscopy the Gold Standard?” by Corley DA, Jensen CD, Chubak J, Schottinger JE, Halm EA, Udaltsova N. Gastroenterology. [2023 Sep;165(3):784-787.e4].
Cannabidiol: A Potential Therapeutic Option for Idiopathic and Diabetic Gastroparesis
Philip Schoenfeld, MD, MSEd, MSc (Epi), Philip Okafor, MD, MPH, and Linda Nguyen, MD discuss “A Randomized Controlled Trial of Efficacy and Safety of Cannabidiol in Idiopathic and Diabetic Gastroparesis,” by Zheng T, BouSaba J, Taylor A et al. Clinical Gastroenterology and Hepatology [2023 Jul 22;S1542-3565(23)00543-8].
American College of Physicians Guidance Statement on Colorectal Cancer Screening: Pitfalls of Second-Guessing Guidelines
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jacqueline Gaulin discuss “Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults: A Guidance Statement from the American College of Physicians (Version 2),” by Qaseem A, Harrod CS, Crandall CJ, et al. Annals of Internal Medicine [2023; 176: 1092-1100].
Long Road to Achieving Competence in Cold Snare Polypectomy: Video-Based Feedback Can Help!
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Swati Patel, MD, MS discuss “Varied Trainee Competence in Cold Snare Polypectomy – Results of the COMPLETE Randomized Controlled Trial,” by Kaltenbach T, Patel SG, Nguyen-Vu T, Malvar C, Keswani RN, Hall M, Aagaard E, Asokkumar R, Chin YK, Hammad H, Rastogi A, Shergill A, Simon V, Soetikno A, Soetikno R, Wani S. Am J Gastroenterol. [2023 Jun 13].
Issue 21
“Cooking Up Something New” with a One-Food Elimination Diet: A Simpler Approach to Dietary Therapy for Eosinophilic Esophagitis
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jennifer Kolb, MD, MS discuss “One-food versus six-food elimination diet therapy for the treatment of eosinophilic esophagitis: a multicenter, randomized, open-label trial,” by Kliewer K, Gonsalves N, Dellon E, et al. Lancet Gastro Hepatol [2023; 8: 408-21].
Kiwifruit-A Specific Food To Improve Stool Frequency in Patients with Mild Constipation
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jacqueline Gaulin discuss “Consumption of 2 Green Kiwifruits Daily Improves Constipation and Abdominal Comfort-Results of an International Multicenter Randomized Controlled Trial,” Gearry R, Fukudo S, Barbara G, et al. Am J Gastroenterol [2023; 118: 1058-68].
ICYMI: Albumin Infusions Do Not Improve Outcomes in Hospitalized Patients with Decompensated Cirrhosis-The ATTIRE Trial
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Nicole Rich, MD, MSCS discuss “A randomized trial of albumin infusions in hospitalized patients with cirrhosis,” by China L, Freemantle N, Forrest E et al. NEJM [2021; 384: 808-817].
Surveillance Colonoscopy Recommendations in Older Adults With Limited Life Expectancy– More Work to be Done!
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Shria Kumar, MD, MSCE discuss “Association of Life Expectancy With Surveillance Colonoscopy Findings and Follow-up Recommendations in Older Adults,” by Calderwood AH, Tosteson TD, Wang Q, et al. JAMA Intern Med. [2023 May 1;183(5):426-34].
Issue 20
Upadacitinib Is Effective for the Induction and Maintenance of Moderate-to-Severe Crohn’s Disease
Rahul Dalal, MD, MPH and Jessica Allegretti, MD, MPH discuss “Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease,” by Loftus EV Jr, Panés J, Lacerda AP, Peyrin-Biroulet L, et al. N Engl J Med [2023 May 25;388(21):1966-1980].
Vedolizumab: An EARNEST Option for the Management of Chronic Pouchitis
Kristin Burke, MD, MPH and Bharati Kochar, MD, MS discuss “Vedolizumab for the Treatment of Chronic Pouchitis,” by Travis S, Silverberg MS, Danese S, et al for the EARNEST Study Group. N Engl J Med [2023 Mar 30;388(13):1191-1200].
Bariatric Surgery Is Superior to Lifestyle Changes + Best Medical Care for Metabolic Dysfunction-Associated Steatohepatitis: The BRAVES Study
Yichin Fu, MD; Sonali Paul, MD, MS discuss “Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial,” by Verrastro O, Panunzi S, Castagneto-Gissey L, et al. Lancet [2023 May 27;401(10390):1786-1797].
Colonoscopy for Colon Polyp Surveillance: Avoid Recommending Early Surveillance
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jacqueline Gaulin discuss “Real-World Compliance with the 2020 US Multi-Society Task Force on Colorectal Cancer Polypectomy Surveillance Guidelines: An Observational Study,” by Dong J, Wang LF, Ardolino E, Feuerstein J. Gastrointest Endosc [2023; 97:350-56].
Issue 19
Free Online Program Improves Adenoma Detection Rate and Decreases Post-Colonoscopy Colorectal Cancer
Jeffrey Lee, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Impact of a Scalable Training Program on the Quality of Colonoscopy Performance and Risk of Post-Colonoscopy Colorectal Cancer,” by Corley DA, Jensen CD, Lee JK, et al. Gastrointest Endosc [2023; In Press].
Screening Colonoscopy in the Elderly Population-Is Less Better?
Philip Okafor, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Frequency of Use and Outcomes in Individuals Older than 75 Years,” by El Halabi J, Burke CA, Hariri E, et al. JAMA Internal Medicine [2023; 183: 513-19].
Cephalosporins and Ciprofloxacin Still Appropriate First-Line Treatment for Spontaneous Bacterial Peritonitis
Jacqueline Gaulin (GastroGirl) and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Response-Guided Therapy with Cefotaxime, Ceftriaxone, or Ciprofloxacin for Spontaneous Bacterial Peritonitis: A Validation Study of 2021 AASLD Practice Guideline for SBP,” by Yim HJ, Kim TH, Suh SJ, et al. Am J Gastroenterol [2023; 118: 654-63].
AGA-ACG Clinical Practice Guideline on Chronic Idiopathic Constipation Treatments: Parsing Benefits and Risks Jacqueline Gaulin (GastroGirl) and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “AGA-ACG Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation,” by Chang L, Chey WD, Imdad A, et al. Am J Gastroenterol [2023; 118: 936-54].
Issue 18
Disposable Elevator Caps for Duodenoscopes Decrease Persistent Bacterial Contamination Without Hindering Technical ERCP Performance: The ICECAP Trial
Shria Kumar, MD, MSCE and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Effect of Disposable Elevator Cap Duodenoscopes on Persistent Microbial Contamination and Technical Performance of Endoscopic Retrograde Cholangiopancreatography: The ICECAP Randomized Clinical Trial,” by Forbes N, Elmunzer BJ, Allain T, et al. JAMA Intern Med [2023;183(3):191-200].
Over-the-Scope Clips Decrease Non-Variceal Upper GI Bleeding vs Standard Endoscopic Treatment… In the Right Patient
Jennifer Kolb, MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Comparison of Over-the-Scope Clips to Standard Endoscopic Treatment as the Initial Treatment in Patients With Bleeding From a Nonvariceal Upper Gastrointestinal Cause: A Randomized Controlled Trial,” by Lau JYW, Li R, Tan C et al. Ann Intern Med [2023 Apr;176(4):455-462].
Prophylactic Antibiotics Do Not Improve Mortality in Severe Alcoholic Hepatitis Treated with Corticosteroids
Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discusses “Effect of Prophylactic Antibiotics on Mortality in Severe Alcohol-Related Hepatitis,” by Louvet A, Labreuche J, Dao T, et al. JAMA [2023; 329 (18): 1558-66].
Issue 17
SEAVUE: a Sea of Change in Biologic Positioning for Crohn’s Disease
Bharati Kochar, MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial,” by Sands BE, Irving PM, Hoops T, et al. Lancet [2022;399(10342):2200-2211].
Jessica Allegretti, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis,” by Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S. N Engl J Med [2019 Sep 26;381(13):1215-1226].
Vibrating Capsules for Chronic Constipation: The New Non-Pharmacologic Approach
Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discusses “Randomized Placebo-Controlled Phase 3 Trial of Vibrating Capsule for Chronic Constipation,” by Rao S, Quigley EMM, Chey WD, et al. Gastroenterology [2023].
ICYMI: Can we prevent hepatic decompensation? Most likely, with nonselective beta blockers.
Sonali Paul, MD, MS, and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomized, double-blind, placebo-controlled, multicenter trial,” by Villanueva C, Albillos A, Genescà J, et al. Lancet [2019, Apr 20;393(10181):1597-1608]. Erratum in: Lancet [2019 Jun 22;393(10190):2492].
Issue 16
Tumor-based screening for Lynch Syndrome: Check Every Colorectal Cancer
Swati G. Patel, MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “A Canadian Provincial Screening Program for Lynch Syndrome,” by Stone JK, Winter R, Khan D, Rothenmund H, Klein J, Chodirker B, Wightman R, Kim CA, Nugent Z, Singh H. American Journal of Gastroenterology [2023;118:345-53].
What are the Causes of Post-colonoscopy Colorectal Cancer?
Jeffrey Lee, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Post-Colonoscopy Colorectal Cancer Etiologies in a Large Integrated US Health Care Setting,” by Leung LJ, Lee JK, Merchant SA, Jensen CD, Alam A, Corley DA. Gastroenterology [2022. PMID: 36462551].
10-Year Intervals After Normal Screening Colonoscopy: It’s Not Too Long with High-Quality Colonoscopy
Philip Okafor MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Prevalence of Colorectal Neoplasia 10 or More Years After A Negative Screening Colonoscopy in 120,000 Repeated Screening Colonoscopies,” by Heisser T, Kretschmann J, Hagen B, et al. JAMA Intern Med [2023; 183: 183-90].
Cold Snare Decreases Post-Polypectomy Bleeding vs Hot Snare for Small (< 10mm) Polyps
Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discusses “Cold Versus Hot Snare Polypectomy for Small Colorectal Polyps: A Pragmatic Randomized Controlled Trial,” by Chang LC, Chang CY, Chen CY, et al. Ann Intern Med [2023; In Press].
Issue 15
Dupilumab, an IgG4 Monoclonal Antibody, for Eosinophilic Esophagitis: Revising the Treatment Paradigm
Afrin Kamal, MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis,” by Dellon ES, Rothenber MH, Collins I, et al. N Engl J Med [2022; 387: 2317-30].
Endoscopic Sleeve Gastroplasty Is Effective for Patients with Obesity Who MERIT Intervention
Jennifer Kolb, MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Endoscopic Sleeve Gastroplasty for Treatment of Class 1 and 2 Obesity (MERIT), a Prospective, Multicentre, Randomised Trial,” by Dayyeh BKA, Bazerbachi F, Vargas EJ, et al. Lancet [2022; 400: 441-51].
Early Colonoscopy for Acute Lower GI Bleeding Usually Is Not the Answer
Shria Kumar, MD, MSCE and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACGdiscuss “Timing of Colonoscopy in Acute Lower GI Bleeding: A Multicenter Retrospective Cohort Study,” by Shiratori Y, Ishii N, Tomonori A, et al. Gastrointest Endosc [2023; 97: 89-99].
Direct-Acting Antiviral Therapy for Hepatitis C Virus Decreases All-Cause Mortality and Decompensated Cirrhosis: Treat (Virtually) Everyone
Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discusses “Association of Direct-Acting Antiviral Therapy with Liver and Nonliver Complications and Long-term Mortality in Patients with Chronic Hepatitis C,” by Ogawa E, Chien N, Kam L, et al. JAMA Internal Medicine [2023; 183: 97-105].
Issue 14
Risankizumab, an Interleukin-23 Inhibitor, for Moderate-Severe Crohn’s Disease: Advancing Care Beyond Anti-TNF Therapy
Bharati Kochar, MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Risankizumab as Induction Therapy for Crohn’s Disease: Results from the Phase 3 ADVANCE and MOTIVATE Induction Trials,” by D’Haens G, Panaccione R, Baert F, et al. Lancet [2022; 399: 2015-30].
Subcutaneous risankizumab is effective and safe for the maintenance of moderate-to-severe Crohn’s disease
Jessica Allegretti, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial,” by Ferrante M, Panaccione R, Baert F, et al. Lancet [2022 May 28;399(10340):2031-2046].
When It’s Not Acid Reflux: Managing PPI-Resistant GERD Patients Based on Bravo Results
Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG and Kristle Lee Lynch, MD discuss “Optimal Wireless Reflux Monitoring Metrics to Predict Discontinuation of Proton Pump Inhibitor Therapy,” by Yadlapati R, Gyawali CP, Masihi M, et al. Am J Gastroenterol [2022 Oct 1;117(10):1573-1582]. [Note: This podcast was updated on February 3, 2023 to include a discussion with Dr Kristle Lee Lynch.]
ICYMI: Is Terlipressin for the Treatment of Hepato-Renal Syndrome Ready for Primetime: Results of the CONFIRM Trial
Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG and Sonali Paul, MD, MSdiscuss “Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome,” by Wong F, Pappas SC, Curry KR, et al. N Engl J Med [2021; 384: 818-28].
Issue 13
Ozanimod, a Selective Selective Sphingosine-1-Phosphatase Receptor Modulator, for Moderate-Severe Ulcerative Colitis: Re-Thinking the Top-Down Treatment Algorithm for UC
Oriana Damas, MDand Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi discuss “Ozanimod for Induction and Maintenance of Ulcerative Colitis,” by Sandborn WJ, Feagan BG, D’Haens G, et al. N Engl J Med [2021; 385: 1280-91].
Continuing Anti-TNF Agents past 24 Weeks of Pregnancy Associated with Fewer IBD Relapses with No Increase in Adverse Fetal Outcomes
Ahmad Abu-Heija, MBBS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Benefits and Risks Associated with Continuation of Anti-Tumor Necrosis Factor After 24 Weeks of Pregnancy in Women With Inflammatory Bowel Disease,” by Meyer A, Neumann A, Drouin J, et al. Ann Intern Med [2022; 175(10) 1374-82].
RBX2660, a Donor Stool Product for Fecal Microbiota Transplant, Decreases Recurrent Clostridioides difficile Infection: The First FDA-Approved Live Biotherapeutic Product
Collen R. Kelly, MD and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection,” by Khanna S, Assi M, Lee C. et al. Drugs [2022; 82: 1527-1538].
NSAID Use and the Risk of IBD Exacerbations: Fact or Fiction
Philip Okafor, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “The Association Between Nonsteroidal Anti-Inflammatory Drug Use and Inflammatory Bowel Disease Exacerbations: A True Association or Residual Bias?” by Cohen-Mekelburg S, Van T, Wallace B, et al. Am J Gastroenterol [2022; 117 (11): 1851-57].
Issue 12
ICYMI: Surgery is Superior to Medical Therapy for PPI-Refractory Heartburn in the “Right” Patients
Jennifer Kolb, MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn,” by Spechler SJ, Hunter JG, Jones KM, et al. N Engl J Med [2019;381:1513-1523].
Vonoprazan, a Potassium-Channel Acid Blocker, is Superior to Lansoprazole for Managing Erosive Esophagitis
Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discusses “Vonoprazan versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial,” by Laine L, DeVault K, Katz P, et al. Gastroenterology [2022; In Press].
Reinvestigating the Lack of Association Between Proton Pump Inhibitor Use and Mortality by Accounting for Reverse Causation
Ravy Vajravelu, MD, MSCE andEditor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Association of Proton Pump Inhibitor Use With All-Cause and Cause-Specific Mortality,” by Lo CH, Ni P, Yan Y, et al. Gastroenterology [2022; 163:852 – 61].
Issue 11
Upadacitinib, a Selective JAK1 Inhibitor, for Moderate-Severe Ulcerative Colitis: Adjusting the Top-Down Treatment Algorithm for UC
Jami Kinnucan, MD and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MSc (Epi) discuss “Upadacitinib as Induction and Maintenance Therapy for Moderately to Severely Active Ulcerative Colitis: Results from Three Phase 3, Multicentre, Double-Blind, Randomised Trials,” by Danese S, Vermeire S, Zhou W, et al, published in Lancet [2022; 399: 2113-28].
Colonoscopy Reduces CRC Incidence and CRC-Related Mortality…. If You Get It!
Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discusses “Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death,” by Bretthauer M, Løberg M, Wieszczy P, et al, published in N Engl J Med [Oct 9, 2022].
High Adenoma Detection Rate Decreases Post-Colonoscopy CRC in FIT-Based Screening Program: Quality Matters!
Joseph Sleiman, MD and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MSc (Epi) discuss “Adenoma Detection Rate and Risk for Interval Postcolonoscopy Colorectal Cancer in Fecal Immunochemical Test-Based Screening: A Population-Based Cohort Study,” by Wisse PHA, Erler N, de Boer SY, et al, published in Ann Intern Med [2022; In Press].
Acute pancreatitis: Need IV fluid resuscitation but avoid a WATERFALL!
Shria Kumar, MD, MSCE and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Aggressive or Moderate Fluid Resuscitation in Acute Pancreatitis,” by de-Madaria E, Buxbaum JL, Maisonneuve P, et al, published in N Engl J Med [2022;387(11):989-1000].
Issue 10
Time to Increase Adenoma Detection Rate Benchmarks for Screening Colonoscopies
Jeffrey Lee, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Association of Physician Adenoma Detection Rates With Postcolonoscopy Colorectal Cancer,” by Schottinger JE, Jensen CD, Ghai NR, et al, published in JAMA [2022 Jun 7;327(21):2114-2122].
Continue Thiopurines and Anti-TNF Agents If Your IBD Patient Becomes Pregnant
Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discusses “Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease,” by Mahadevan U, Long MD, Kane SV, et al, published in Gastroenterology [2021 Mar;160(4):1131-1139].
Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discusses “Exposure to Corticosteroids in Pregnancy Is Associated with Adverse Perinatal Outcomes Among Infants of Mothers with Inflammatory Bowel Disease,” by Odufalu FD, Long MD, Lin K, Mahadaven U for PIANO Investigators, published in GUT [2022; 71: 1766-72].
ICYMI-Pantoprazole Prophylaxis Does Not Reduce 90-day Mortality and Clinically Significant Adverse Events in ICU Patients
Philip Okafor, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Pantoprazole in Patients at Risk for Gastrointestinal for Gastrointestinal Bleeding in the ICU,” by Krag M, Marker S, Perner A et al, published in NEJM [379; 23: 2018].
Issue 9
Swati Patel, MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Serrated polyp detection and risk of interval post-colonoscopy colorectal cancer: a population-based study,” by van Toledo et al, published in Lancet Gastroenterol Hepatol [2022 Aug;7(8):747-754]. https://pubmed.ncbi.nlm.nih.gov/35550250/
Tiny Polyps-It’s OK to Remove Polyps < 3mm with Large Biopsy Forceps
Shria Kumar, MD, MSCE and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Randomized Controlled Trial Investigating Cold Snare and Forceps Polypectomy Among Small POLYPs in Rates of Complete Resection: The TINYPOLYP Trial,” by Wei et al, published in Am J Gastroenterol [2022 Aug 1;117(8):1305-1310]. https://pubmed.ncbi.nlm.nih.gov/35467557/
Prophylactic Rifaximin Decreases Post-TIPS Hepatic Encephalopathy
Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discusses “The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial,” by Bureau et al, published in Ann Intern Med [2021 May;174(5):633-640].https://pubmed.ncbi.nlm.nih.gov/33524293/
Issue 8
Treating H.pylori Infection with Vonoprazan, a Potassium-Competitive Acid Blocker: A New Paradigm
Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discusses “Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the US and Europe: A Randomized Controlled Trial,” by Chey, et al, published in Gastroenterology [2022; In Press]. https://pubmed.ncbi.nlm.nih.gov/35679950/
Jennifer Kolb, MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Endoscopic or Surgical Myotomy in Patients with Idiopathic Achalasia,” by Werner et al, published in N Engl J Med [2019;381:2219-2229]. https://pubmed.ncbi.nlm.nih.gov/31800987/
Does Choice of Anticoagulant Influence Risk of Gastrointestinal Bleeding?
Ravy K. Vaajravelu, MD, MSCE and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Rivaroxaban Is Associated With Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants : A Nationwide Propensity Score-Weighted Study,” by Ingason et al, published in Ann Intern Med [2021 Nov;174(11):1493-1502]. https://pubmed.ncbi.nlm.nih.gov/34633836/
Philip Okafor, MD and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Adenoma Detection Rates in 45-49-Year-Old Persons Undergoing Screening Colonoscopy: Analysis From the GIQuIC Registry,” by Bilal et al, published in Am J Gastroenterol [2022 May 1;117(5):806-808]. https://pubmed.ncbi.nlm.nih.gov/35169107/
Issue 7
SER-109, an Oral Microbiome Therapy, Decreases Recurrent Clostridiodes difficile Infection
Jessica Allegretti, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection” by Feuerstadt et al, published in N Engl J Med [2022;386(3):220-229]. https://pubmed.ncbi.nlm.nih.gov/35045228/
When Is Routine Prophylactic Clipping Indicated Post-Polypectomy?
Jeffrey Lee, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Effect of prophylactic endoscopic clip placement on clinically significant post-endoscopic mucosal resection bleeding in the right colon: a single-centre, randomised controlled trial” by Gupta et al, published in Lancet Gastroenterol Hepatol [2022;7(2):152-160]. https://pubmed.ncbi.nlm.nih.gov/34801133/
Tenapanor (IBSRELA) for Treatment of IBS-C: Effective over 26 Weeks
Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discusses “Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome with Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2)” by Chey et al, published in Am J Gastroenterol [2021;116: 1294-1303]. https://pubmed.ncbi.nlm.nih.gov/33337659/
Issue 6
Shria Kumar, MD, MSCE and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Discordance Among Pathologists in the United States and Europe in Diagnosis of Low-Grade Dysplasia for Patients With Barrett’s Esophagus” by Vennalaganti et al, published in Gastroenterology [2017 Feb;152(3):564-570.e4]. https://pubmed.ncbi.nlm.nih.gov/27818167/
Issue 5
Jessica R. Allegretti, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial” by Syversen et al, published in JAMA [2021; 326(23):2375-2384]. https://pubmed.ncbi.nlm.nih.gov/34932077/
Jennifer M Kolb MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Long-term Outcomes after Endoscopic Treatment for Barrett’s Neoplasia with Radiofrequency Ablation ± Endoscopic Resection: Results from the National Dutch Database in a 10-year Period” by Munster et al, published in Gut [2022;71:265-76]. https://pubmed.ncbi.nlm.nih.gov/33753417/
Issue 4
Jeffrey Lee, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Recurrence of Colorectal Neoplastic Polyps After Incomplete Resection” by Pohl et al, published in Annals of Internal Medicine. [2021;174(10):1377-1384]. https://pubmed.ncbi.nlm.nih.gov/34370514/
Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discusses “A Multicenter Randomized Controlled Trial Comparing Bowel Cleansing Regimens for Colonoscopy After Failed Bowel Preparation” by Sey at al, published in Clinical Gastroenterology and Hepatology [2022;In Press]. https://pubmed.ncbi.nlm.nih.gov/34256147
Sonali Paul, MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Effects of Time-Restricted Eating on Weight Loss and Other Metabolic Parameters in Women and Men with Overweight and Obesity. The TREAT Randomized Clinical Trial” by Lowe et al, published in JAMA [2021; 181(6):883]. https://pubmed.ncbi.nlm.nih.gov/32986097/
Family Matters: Increased Risk of Colorectal Cancer among Individuals with Family History of Polyps
Ravy K. Vajravelu, MD, MSCE and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Risk of colorectal cancer in first degree relatives of patients with colorectal polyps: nationwide case-control study in Sweden” by Song et al, published in BMJ [2021;373:n877]. https://pubmed.ncbi.nlm.nih.gov/33947661/
Issue 3
Jennifer M. Kolb MD, MSCS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi, FACG discuss “Impact of 9-Minute Withdrawal Time on the Adenoma Detection Rate: A Multicenter Randomized Controlled Trial” by Zhao et al, published in Clinical Gastroenterology and Hepatology [2020;20:31553-6]. https://pubmed.ncbi.nlm.nih.gov/33220526/
Drainage for Infected Pancreatic Necrosis – Earlier Is Not Better
Shria Kumar, MD, MSCE and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi, FACG discuss “Immediate versus Postponed Intervention for Infected Necrotizing Pancreatitis” by Boxhoorn et al, published in NEJM. [2021;15:1372-1381]. https://pubmed.ncbi.nlm.nih.gov/34614330/
Hereditary Syndrome Risk Assessment in all Colorectal Cancer Patients: Keep it Simple!
Swati Patel, MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi, FACG discuss “Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative” by Pearlman et al, published in JCO Precision Oncology [2021;5:779-91]. https://pubmed.ncbi.nlm.nih.gov/34250417/
Treating All the Symptoms of IBS-C: Linaclotide Significantly Decreases Abdominal Pain, Bloating, and Discomfort
Jill Deutsch, MD and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi, FACG discuss “Efficacy of Linaclotide in Reducing Abdominal Symptoms of Bloating, Discomfort, and Pain: A Phase 3B Trial Using a Novel Abdominal Scoring System” by Chang et al, published in American Journal of Gastroenterology [2021;116: 1929-37]. https://pubmed.ncbi.nlm.nih.gov/34465695/
Issue 2
Philip N. Okafor, MD, MPH discusses the recent AJG article “A Safety and Efficacy Comparison of a New Sulfate-Based Tablet Bowel Preparation Versus a PEG and Ascorbate Comparator in Adult Subjects Undergoing Colonoscopy.” This RCT compares SUTAB®, a sodium sulfate tablet bowel preparation, to MoviPrep®. Since it is a hyperosmolar prep, be cautious when using it in patients with congestive heart failure, renal insufficiency, or electrolyte abnormalities.
Sonali Paul, MD, MS discusses “A Placebo-Controlled Trial of Subcutaneous Semaglutide,” published in NEJM in May 2021. Semaglutide, a GLP-1 receptor agonist for type II diabetes mellitus and weight loss, shows potential as a treatment for NASH in a well-designed, placebo-controlled RCT. May need longer trials to see if it can resolve fibrosis, which is a key treatment goal. Will anxiously await results from ongoing study of weekly high-dose semaglutide in NASH patients.
Shria Kumar, MD, MSCE discusses a 2020 article in Gastroenterology, “Efficacy of Real-Time Computer-Aided Detection of Colorectal Neoplasia in a Randomized Trial.” GI-Genius™, a new computer-aided adenoma detection tool, is FDA-approved, integrates into existing endoscopic systems, and overlays a detection box around a potential polyp. In a well-designed RCT, adenoma detection was significantly higher with GI-Genius™. Endoscopists will need to consider a variety of factors to determine whether to integrate this tool into their endoscopy practice.
Issue 1
Piecemeal Cold Snare Polypectomy of Large SSP: Cold Is the New Hot
Swati Patel, MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi, FACG discuss Piecemeal cold snare polypectomy versus conventional endoscopic mucosal resection for large sessile serrated lesions: a retrospective comparison across two successive periods bt Van Hattem WA, published in Gut [2021;70:1691-97]. https://doi.org/10.1136/gutjnl-2020-321753
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Sonali Paul, MD, MS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi, FACG discuss Semaglutide Treatment Effect in People with Obesity (STEP) Investigators. Once-Weekly Semaglutide in Adults with Overweight or Obesity by Wilding et al, published in the New England Journal of Medicine [2021; 384: 989-1002. https://www.nejm.org/doi/10.1056/NEJMoa2032183
Jeffrey Lee, MD, MPH and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi, FACG discuss Association of Screening Lower Endoscopy with Colorectal Cancer Incidence and Mortality in Adults Older than 75 Years by Ma et al, published in .JAMA Oncology [2021;7(7):985-992]. https://doi.org/10.1001/jamaoncol.2021.1364
Acute Myeloid Leukemia and Myelodysplastic Syndrome with IBD and Thiopurines Impact on Risk
Ravy K. Vajravelu, MD, MSCE and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi, FACG discuss Incidence of Acute Myeloid Leukemia and Myelodysplastic Syndrome in Patients with Inflammatory Bowel Disease and the Impact of Thiopurines on Their Risk by Kahn et al., published in The American Journal of Gastroenterology [2021; 116: 741-47]. www.doi.org/10.14309/ajg.0000000000001058